Diabetic mice treated with the LOXL2 inhibitor had significant reduction in the glomerulosclerosis score (P < 0.05 vs. DM, Fig. 3C), whereas the reduction in the telmisartan group was statistically not significant (Fig. 3D). The gene discussed is LOXL2; the disease is diabetes mellitus.